Pfizer nears deal with Trump administration to provide more Covid-19 vaccine doses

In the negotiations, the government is asking for 100 million additional doses from Pfizer from April through June. PHOTO: AFP

NEW YORK (NYTIMES) - The Trump administration and Pfizer are close to a deal under which the pharmaceutical company would bolster supply of its coronavirus vaccine for the United States by at least tens of millions of doses next year in exchange for a government directive giving it better access to manufacturing supplies, people familiar with the discussions said.

An agreement, which could be announced as early as Wednesday (Dec 23), would help the United States at least partly offset a looming vaccine shortage that could leave as many as 110 million adult Americans uncovered in the first half of 2021.

So far, only two pharmaceutical companies - Pfizer and Moderna - have won federal authorisation for emergency distribution of Covid-19 vaccines, and most of what they are capable of producing for the next six months has already been allocated through contracts with the United States and other governments.

In the negotiations, the government is asking for 100 million additional doses from Pfizer from April through June. The company has signalled that it should be able to produce at least 70 million, and perhaps more, if it can get more access to supplies and raw materials.

To help Pfizer, the deal calls for the government to invoke the Defence Production Act to give the company better access to roughly nine specialised products it needs to make the vaccine.

One person familiar with the list said it included lipids, the oily molecules in which the genetic material that is used in both the Moderna and Pfizer vaccines is encased.

Pfizer first started asking for the government's help in obtaining supplies as early as September and has been unhappy about the lack of response, according to documents reviewed by The New York Times.

Moderna and other companies that worked more closely than Pfizer with the administration through its Operation Warp Speed to develop their vaccines already receive favoured treatment from suppliers, putting Pfizer at a disadvantage. That includes two companies - Sanofi and Novavax - that have yet to begin large-scale clinical trials in the United States.

Pfizer and the administration have been negotiating for more doses from Pfizer for more than a month. But a host of other issues have stood in the way of a deal, including Pfizer's commitments to other nations that moved faster than the United States to lock in a big supply, according to people familiar with the situation.

Pfizer already has a federal contract, signed in July, to deliver 100 million doses of its vaccine by the end of March. Moderna has the same agreement, and has also pledged to sell the government 100 million more doses in the second quarter of the year, from the start of April to the end of June.

Because the Pfizer and the Moderna vaccine both require two doses, that supply would cover only 150 million Americans out of the roughly 260 million who are eligible at the moment to be vaccinated. (Moderna's vaccine is now restricted to those 18 and over, and Pfizer's is limited to those 16 and over.)

If Pfizer provides another 100 million doses, that would leave about 60 million eligible Americans uncovered in the first half of the year. Other producers could also cover the shortfall should their vaccines prove successful.

It is not clear how many more doses Pfizer can quickly produce even if the administration uses the Defence Production Act to clear away supply obstacles. One person familiar with the situation said the firm may only be able to deliver 70 million by the end of June, even with better access to supplies.

Had the government agreed to prioritise its supply needs earlier, one person familiar with Pfizer's situation said, the company might be better positioned now to fully meet the demands. Documents reviewed by The Times showed that Pfizer officials began asking General Gustave Perna, the chief operating officer of Operation Warp Speed, in September for help with supplies and brought up the issue repeatedly in weekly meetings.

A senior Trump administration official said the government was unwilling to intervene because Pfizer refused to promise that it would use those materials to produce vaccines solely for Americans.

"It's our obligation under that type of priority rating to make sure that assets are used only for US sales or production," the official said, "and they weren't willing to do that."

People knowledgeable about the talks said Gen Perna had raised a different concern with Pfizer, saying the government wanted to protect its investment in the other companies under Warp Speed's umbrella, so it did not want to grant Pfizer the same priority with supplies.

According to a report last month by the Government Accountability Office, the Defence Production Act gives the federal government vast authority over private companies, including the power to prevent supplies from being diverted to a different purpose or products from being sold overseas.

The administration has granted the kind of status that Pfizer has been seeking to multiple contractors for medical supplies since the pandemic began, including companies that produce ventilators and N95 respirators, the report states.

Because the Pfizer vaccine, developed with the German company BioNTech, is one of only two that the Food and Drug Administration has approved for emergency use, the company has had leverage in negotiating the new contract.

That advantage could erode if other vaccines are authorised. A third firm, Johnson & Johnson, is expected to announce results from its clinical trials next month. A fourth, AstraZeneca, has announced some interim results, but it has yet to fully enroll its trial in the United States.

With infections, hospitalisations and deaths surging to record levels from a pandemic that has already killed more than 320,000 Americans, the pressure on Pfizer and the government to come to terms is growing.

"The last thing we want is for this to turn acrimonious," said Dr Walid Gellad, who leads the Centre for Pharmaceutical Policy and Prescribing at the University of Pittsburgh. "This kind of corrosive back-and-forth is not helping the public feel any better about what's going to happen in the future."

Pfizer's relationship with the administration has been tense for months. After he lost the election in November, President Donald Trump accused Pfizer of deliberately slow-walking federal approval of its vaccine to hurt him politically.

Join ST's Telegram channel and get the latest breaking news delivered to you.